Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADCY1 | Q08828 | 6/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21525527 | 0.82 | ADCY1 (0.39) | CA1CA2EPHX2MEN1MAPT | |
| SCHEMBL29546533 | 0.81 | PARP1 (0.39) | MAPTKMT2A | |
| SCHEMBL24724145 | 0.80 | KMT2A (0.46) | CA1CA2EPHX2MEN1MAPT | |
| Lithium Ion SCHEMBL31084591 | 0.78 | EPHX2 (0.40) | CA1CA2EPHX2MEN1MAPT | |
| SCHEMBL8840127 | 0.74 | ADCY1 (0.47) | CA1CA2EPHX2MAPTKMT2A | |
| Trifluoroacetic Acid SCHEMBL29546259 | 0.74 | PARP1 (0.34) | — | |
| SCHEMBL20305423 | 0.72 | CA1 (0.43) | CA1CA2MEN1MAPTKMT2A | |
| SCHEMBL442998 | 0.72 | PKM (0.41) | EPHX2MEN1KMT2AADCY1PKM | |
| SCHEMBL29545615 | 0.70 | — | — | |
| SCHEMBL439761 | 0.69 | NPC1 (0.42) | CA1CA2EPHX2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6462198-B1 | USED IN THE CONTROL OR PREVENTION OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS RESTRICTED BRAIN FUNCTION CAUSED BY BYPASS OPERATIONS OR TRANSPLANTS, POOR BLOOD SUPPLY TO THE BRAIN, SPINAL CORD INJURIES, HEAD INJURIES, HYPOXIA, | HOFFMANN-LA ROCHE INC. | 2002-10-08 | — | — | US | claimed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| EP-1171423-B1 | CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2005-01-12 | — | — | EP | disclosed |
| US-6803381-B1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS, ACTING AS ANTAGONISTS OR AGONISTS | HOFFMANN-LA ROCHE INC. | 2004-10-12 | — | — | US | disclosed |
| US-6596743-B2 | Control or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| US-6462198-B1 | USED IN THE CONTROL OR PREVENTION OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS RESTRICTED BRAIN FUNCTION CAUSED BY BYPASS OPERATIONS OR TRANSPLANTS, POOR BLOOD SUPPLY TO THE BRAIN, SPINAL CORD INJURIES, HEAD INJURIES, HYPOXIA, | HOFFMANN-LA ROCHE INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020091150-A1 | Carbamic acid derivatives | BLEICHER KONRAD (DE) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091150-A1 | Carbamic acid derivatives | CHRM1, CHRNA2, CHRM2 | CA1 174/4885CA2 311/4885EPHX2 2047/4885 |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | CA1 4651/4885CA2 3870/4885EPHX2 4325/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | CA1 3768/4885CA2 1534/4885EPHX2 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.